Published in Bull Cancer on August 01, 2002
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol (2012) 5.86
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol (2006) 5.56
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol (2009) 4.27
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol (2007) 2.10
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res (2013) 2.03
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer (2004) 1.54
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone. Anticancer Drugs (2012) 1.45
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res (2002) 1.36
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer (2002) 1.24
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology (2011) 1.16
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer (2005) 1.14
Targeted agents for adjuvant therapy of colon cancer. Semin Oncol (2006) 1.12
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol (2010) 1.11
Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol (2012) 1.07
From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol (2011) 1.07
Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol (2007) 1.05
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist (2011) 1.05
Cetuximab-induced acne. Dermatology (2005) 0.99
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res (2011) 0.98
Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer (2009) 0.97
Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit (2005) 0.96
Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int (2006) 0.96
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer (2011) 0.95
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest (2006) 0.94
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol (2005) 0.94
Regorafenib for metastatic colorectal cancer. Lancet (2013) 0.94
Stage II and stage III colon cancer: treatment advances and future directions. Cancer J (2010) 0.90
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. Bull Cancer (2006) 0.90
The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer (2011) 0.90
Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol (2011) 0.90
Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer (2010) 0.90
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol (2003) 0.89
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer (2012) 0.87
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest (2003) 0.87
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer (2007) 0.86
Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer (2013) 0.86
Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol (2004) 0.86
Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol (2008) 0.84
A mucoepidermoid carcinoma in a young man with intellectual disability: review of oral cancer in people with intellectual disability. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.84
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg (2009) 0.84
Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res (2002) 0.83
Cetuximab in advanced bladder cancer. J Clin Oncol (2013) 0.83
Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin Chem (2003) 0.83
Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol (2005) 0.82
A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer (2003) 0.82
Targeted therapies in metastatic renal cancer in 2009. BJU Int (2009) 0.82
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer (2013) 0.81
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
[HER2 and gastric cancer. Recommendations for clinical practice in 2011]. Ann Pathol (2011) 0.81
[Malignant biliary obstruction, general review and clinical practice]. Bull Cancer (2013) 0.80
Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. Cancer Chemother Pharmacol (2002) 0.80
Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol (2009) 0.80
Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy. J Thorac Oncol (2014) 0.80
[Adjuvant treatment of colorectal cancer]. Bull Cancer (2006) 0.80
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer (2014) 0.79
[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?]. Prog Urol (2006) 0.79
Awareness on oral cancer in people with intellectual disability. Oral Oncol (2012) 0.79
Prognostic factors for first recurrence in patients with retroperitoneal sarcoma. Urol Oncol (2006) 0.79
Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist (2014) 0.79
[Penile tumors]. Prog Urol (2007) 0.79
A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21. Urol Int (2009) 0.79
Abiraterone acetate withdrawal syndrome: does it exist? Case Rep Oncol (2012) 0.78
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. J Chemother (2013) 0.78
A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs (2002) 0.78
Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin Colorectal Cancer (2010) 0.78
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer (2012) 0.78
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1). Clin Colorectal Cancer (2010) 0.78
Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. Aging Male (2014) 0.77
Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol (2007) 0.77
Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. Int J Urol (2009) 0.77
Cetuximab efficacy in patients treated routinely in university hospitals. Gastroenterol Clin Biol (2007) 0.77
[Renal cell carcinoma and antiangiogenic therapies]. Presse Med (2007) 0.77